Q32 Bio Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Q32 Bio Inc Company

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Q32 Bio Inc Info



Ticker SymbolQTTB

Company nameQ32 Bio Inc

IPO dateMar 28, 2018

CEOMs. Jodie Pope Morrison

Number of employees42

Security typeOrdinary Share

Fiscal year-endMar 28

Address830 Winter Street

CityWALTHAM

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code02451

Phone17819990232

Websitehttps://www.q32bio.com/

Ticker SymbolQTTB

IPO dateMar 28, 2018

CEOMs. Jodie Pope Morrison

Company Executives of Q32 Bio Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Shelia M. Violette, Ph.D.

Chief Scientific Officer, President of Research

57.16K

-4.97%

Ms. Kathleen D. Laporte

Independent Director

5.43K

--

Dr. David S. Grayzel, M.D.

Independent Director

--

Dr. Bill Lundberg, M.D.

Independent Director

--

Ms. Jodie Pope Morrison

Chief Executive Officer, Director

--

-100.00%

Mr. Lee H. Kalowski

President, Chief Financial Officer

--

Mr. Mark T. Iwicki

Independent Chairman of the Board

--

Mr. Diyong Xu

Independent Director

--

Dr. Isaac Manke

Independent Director

--

Ms. Mary T. Thistle, CPA

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Shelia M. Violette, Ph.D.

Chief Scientific Officer, President of Research

57.16K

-4.97%

Ms. Kathleen D. Laporte

Independent Director

5.43K

--

Dr. David S. Grayzel, M.D.

Independent Director

--

Dr. Bill Lundberg, M.D.

Independent Director

--

Ms. Jodie Pope Morrison

Chief Executive Officer, Director

--

-100.00%

Mr. Lee H. Kalowski

President, Chief Financial Officer

--

Revenue Breakdown

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

No Data

By RegionUSD

Name

Revenue

Proportion

United States

0.00

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

OrbiMed Advisors, LLC

18.47%

Atlas Venture

17.15%

Abingworth Management Limited

9.04%

Acorn Capital Advisors, LLC

6.59%

ARCH Venture Partners

2.63%

Other

46.12%

Shareholders

Proportion

OrbiMed Advisors, LLC

18.47%

Atlas Venture

17.15%

Abingworth Management Limited

9.04%

Acorn Capital Advisors, LLC

6.59%

ARCH Venture Partners

2.63%

Other

46.12%

Shareholder Types

Shareholders

Proportion

Venture Capital

28.82%

Private Equity

18.47%

Investment Advisor

17.55%

Corporation

5.92%

Hedge Fund

1.98%

Investment Advisor/Hedge Fund

1.72%

Research Firm

1.17%

Individual Investor

0.62%

Other

23.75%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

197

8.50M

69.71%

-4.30M

2025Q2

211

9.72M

79.73%

-4.89M

2025Q1

223

10.26M

84.16%

-4.38M

2024Q4

223

11.35M

93.20%

-1.04M

2024Q3

208

11.60M

102.62%

+2.77M

2024Q2

197

10.02M

90.20%

+1.83M

2024Q1

230

9.37M

85.14%

+7.24M

2023Q4

242

1.68M

52.16%

-377.72K

2023Q3

262

1.62M

50.50%

-460.61K

2023Q2

275

1.63M

50.84%

-543.11K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

OrbiMed Advisors, LLC

2.25M

18.47%

--

Jun 30, 2025

Atlas Venture

2.09M

17.15%

--

Jun 30, 2025

Abingworth Management Limited

1.10M

9.04%

--

Jun 30, 2025

Acorn Capital Advisors, LLC

803.42K

6.59%

--

Jun 30, 2025

ARCH Venture Partners

320.48K

2.63%

--

Jun 30, 2025

Monaco asset management S.A.M.

591.94K

4.85%

+86.49K

+17.11%

Jun 30, 2025

The Vanguard Group, Inc.

269.43K

2.21%

-39.78K

-12.87%

Jun 30, 2025

Pfizer Inc

277.78K

2.28%

--

Jun 30, 2025

Sanofi SA

244.08K

2%

--

Jun 30, 2025

Bristol Myers Squibb

200.24K

1.64%

-558.90K

-73.62%

Dec 31, 2024

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Fidelity Enhanced Small Cap ETF

0%

iShares Russell 2000 ETF

0%

Hypatia Women CEO ETF

0%

Invesco Nasdaq Biotechnology ETF

0%

ProShares UltraPro Russell2000

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

Goldman Sachs Innovate Equity ETF

0%

iShares Micro-Cap ETF

0%

iShares Russell 2000 Value ETF

0%

Avantis US Small Cap Equity ETF

0%

Fidelity Enhanced Small Cap ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Hypatia Women CEO ETF

Proportion0%

Invesco Nasdaq Biotechnology ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

Goldman Sachs Innovate Equity ETF

Proportion0%

iShares Micro-Cap ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

Avantis US Small Cap Equity ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1

Date

Type

Ratio

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1

Mar 20, 2024

Merger

18→1